Organic Chemical
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery
FDA Approves Label Changes for Indivior’s Sublocade, Enhancing Treatment Accessibility for Opioid Use Disorder
Sublocade, FDA approval, rapid initiation protocol, alternative injection sites, opioid use disorder treatment
FDA Approves Mirum’s Ctexli as First Treatment for Rare Lipid Disorder CTX
Ctexli, chenodiol, cerebrotendinous xanthomatosis (CTX), FDA approval, Mirum Pharmaceuticals, rare metabolic disorder, lipid storage disease, bile acid therapy
Gilead’s Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment
Seladelpar, Gilead Sciences, primary biliary cholangitis, PBC, European Commission, conditional marketing authorization, RESPONSE trial, ursodeoxycholic acid (UDCA)
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens
Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio
Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor
Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations
Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback